Search Results - "Bruce E. Johnson"

The impact of genomic changes on treatment of lung cancer by CARDARELLA, Stephanie, JOHNSON, Bruce E

“…The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR…”
Get full text

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer by Wang, Xinan, Ricciuti, Biagio, Nguyen, Tom, Li, Xihao, Rabin, Michael S, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

“…Lung carcinogenesis is a complex and stepwise process involving accumulation of genetic mutations in signaling and oncogenic pathways via interactions with…”
Get full text

Dabrafenib plus trametinib in patients with previously treated BRAFV600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial by Planchard, David, MD, Besse, Benjamin, MD, Groen, Harry J M, Prof, Souquet, Pierre-Jean, MD, Quoix, Elisabeth, Prof, Baik, Christina S, MD, Barlesi, Fabrice, Prof, Kim, Tae Min, MD, Mazieres, Julien, Prof, Novello, Silvia, MD, Rigas, James R, MD, Upalawanna, Allison, PharmD, D'Amelio, Anthony M, PhD, Zhang, Pingkuan, MD, Mookerjee, Bijoyesh, MD, Johnson, Bruce E, Prof

“…Summary Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC)…”
Get full text

A single-cell landscape of high-grade serous ovarian cancer by Izar, Benjamin, Tirosh, Itay, Stover, Elizabeth H., Wakiro, Isaac, Cuoco, Michael S., Alter, Idan, Rodman, Christopher, Leeson, Rachel, Su, Mei-Ju, Shah, Parin, Iwanicki, Marcin, Walker, Sarah R., Kanodia, Abhay, Melms, Johannes C., Mei, Shaolin, Lin, Jia-Ren, Porter, Caroline B. M., Slyper, Michal, Waldman, Julia, Jerby-Arnon, Livnat, Ashenberg, Orr, Brinker, Titus J., Mills, Caitlin, Rogava, Meri, Vigneau, Sébastien, Sorger, Peter K., Garraway, Levi A., Konstantinopoulos, Panagiotis A., Liu, Joyce F., Matulonis, Ursula, Johnson, Bruce E., Rozenblatt-Rosen, Orit, Rotem, Asaf, Regev, Aviv

“…Malignant abdominal fluid (ascites) frequently develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with drug resistance…”
Get full text

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints by Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.

“…Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung…”
Get full text

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium by Pillai, Rathi N., Behera, Madhusmita, Berry, Lynne D., Rossi, Mike R., Kris, Mark G., Johnson, Bruce E., Bunn, Paul A., Ramalingam, Suresh S., Khuri, Fadlo R.

“…BACKGROUND Human epidermal growth factor receptor 2 (HER2) mutations have been reported in lung adenocarcinomas. Herein, the authors describe the prevalence,…”
Get full text

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial by Planchard, David, MD, Kim, Tae Min, MD, Mazieres, Julien, Prof, Quoix, Elisabeth, Prof, Riely, Gregory, MD, Barlesi, Fabrice, Prof, Souquet, Pierre-Jean, MD, Smit, Egbert F, Prof, Groen, Harry J M, Prof, Kelly, Ronan J, MD, Cho, B C, MD, Socinski, Mark A, Prof, Pandite, Lini, MD, Nase, Christine, BSN, Ma, Bo, PhD, D'Amelio, Anthony, PhD, Mookerjee, Bijoyesh, MD, Curtis, C Martin, BS, Johnson, Bruce E, Prof

“…Summary Background Activating BRAFV600E (Val600Glu) mutations are found in about 1–2% of lung adenocarcinomas, which might provide an opportunity for targeted…”
Get full text

State of the art: Response assessment in lung cancer in the era of genomic medicine by Nishino, Mizuki, Hatabu, Hiroto, Johnson, Bruce E, McLoud, Theresa C

“…Tumor response assessment has been a foundation for advances in cancer therapy. Recent discoveries of effective targeted therapy for specific genomic…”
Get full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs by Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

“…IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung…”
Get full text

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing by Imielinski, Marcin, Berger, Alice H., Hammerman, Peter S., Hernandez, Bryan, Pugh, Trevor J., Hodis, Eran, Cho, Jeonghee, Suh, James, Capelletti, Marzia, Sivachenko, Andrey, Sougnez, Carrie, Auclair, Daniel, Lawrence, Michael S., Stojanov, Petar, Cibulskis, Kristian, Choi, Kyusam, de Waal, Luc, Sharifnia, Tanaz, Brooks, Angela, Greulich, Heidi, Banerji, Shantanu, Zander, Thomas, Seidel, Danila, Leenders, Frauke, Ansén, Sascha, Ludwig, Corinna, Engel-Riedel, Walburga, Stoelben, Erich, Wolf, Jürgen, Goparju, Chandra, Thompson, Kristin, Winckler, Wendy, Kwiatkowski, David, Johnson, Bruce E., Jänne, Pasi A., Miller, Vincent A., Pao, William, Travis, William D., Pass, Harvey I., Gabriel, Stacey B., Lander, Eric S., Thomas, Roman K., Garraway, Levi A., Getz, Gad, Meyerson, Matthew

“…Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, is responsible for more than 500,000 deaths per year worldwide. Here, we report…”
Get full text

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer by Wang, Xinan, Ricciuti, Biagio, Alessi, Joao V, Nguyen, Tom, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

“…Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a subset of patients, consistent and easily obtainable predictors of efficacy remain…”
Get full text

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer by JACKMAN, David, PAO, William, RIELY, Gregory J, ENGELMAN, Jeffrey A, KRIS, Mark G, JÄNNE, Pasi A, LYNCH, Thomas, JOHNSON, Bruce E, MILLER, Vincent A

“…Ten percent of North American patients with non-small-cell lung cancer have tumors with somatic mutations in the gene for the epidermal growth factor receptor…”
Get full text

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting by EBERHARD, David A, GIACCONE, Giuseppe, JOHNSON, Bruce E

“…The body of literature on the correlations between molecular assessments and patient outcomes after treatment with epidermal growth factor receptor (EGFR)…”
Get full text

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience by Sholl, Lynette M, Aisner, Dara L, Varella-Garcia, Marileila, Berry, Lynne D, Dias-Santagata, Dora, Wistuba, Ignacio I, Chen, Heidi, Fujimoto, Junya, Kugler, Kelly, Franklin, Wilbur A, Iafrate, A John, Ladanyi, Marc, Kris, Mark G, Johnson, Bruce E, Bunn, Paul A, Minna, John D, Kwiatkowski, David J

“…Molecular genetic analyses of lung adenocarcinoma have recently become standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed…”
Get more information

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions by Oxnard, Geoffrey R, Lo, Peter C, Nishino, Mizuki, Dahlberg, Suzanne E, Lindeman, Neal I, Butaney, Mohit, Jackman, David M, Johnson, Bruce E, Jänne, Pasi A

“…Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is…”
Get more information

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC by Alessi, Joao V., Ricciuti, Biagio, Wang, Xinan, Pecci, Federica, Di Federico, Alessandro, Lamberti, Giuseppe, Elkrief, Arielle, Rodig, Scott J., Lebow, Emily S., Eicholz, Jordan E., Thor, Maria, Rimner, Andreas, Schoenfeld, Adam J., Chaft, Jamie E., Johnson, Bruce E., Gomez, Daniel R., Awad, Mark M., Shaverdian, Narek

“…Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC),…”
Get full text

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer by JOHNSON, Bruce E, KABBINAVAR, Fairooz, RUBIN, Mark, WHITE, Leonard, YANG, James Chih-Hsin, BOWDEN, Chris, MILLER, Vincent, FEHRENBACHER, Louis, HAINSWORTH, John, KASUBHAI, Saifuddin, KRESSEL, Bruce, LIN, Chin-Yu, MARSLAND, Thomas, PATEL, Taral, POLIKOFF, Jonathan

“…This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with…”
Get full text

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population by RODIG, Scott J, MINO-KENUDSON, Mari, JANNE, Pasi A, LYNCH, Thomas, JOHNSON, Bruce E, LAFRATE, A. John, CHIRIEAC, Lucian R, DACIC, Sanja, YEAP, Beow Y, SHAW, Alice, BARLETTA, Justine A, STUBBS, Hannah, LAW, Kenny, LINDEMAN, Neal, MARK, Eugene

“…Purpose: The anaplastic large cell kinase gene ( ALK ) is rearranged in ∼5% of lung adenocarcinomas within the Asian population. We evaluated the incidence and…”
Get full text

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium by Steuer, Conor E., Behera, Madhusmita, Berry, Lynne, Kim, Sungjin, Rossi, Michael, Sica, Gabriel, Owonikoko, Taofeek K., Johnson, Bruce E., Kris, Mark G., Bunn, Paul A., Khuri, Fadlo R., Garon, Edward B., Ramalingam, Suresh S.

“…BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities…”
Get full text

The BATTLE trial: personalizing therapy for lung cancer by Kim, Edward S, Herbst, Roy S, Wistuba, Ignacio I, Lee, J Jack, Blumenschein, Jr, George R, Tsao, Anne, Stewart, David J, Hicks, Marshall E, Erasmus, Jr, Jeremy, Gupta, Sanjay, Alden, Christine M, Liu, Suyu, Tang, Ximing, Khuri, Fadlo R, Tran, Hai T, Johnson, Bruce E, Heymach, John V, Mao, Li, Fossella, Frank, Kies, Merrill S, Papadimitrakopoulou, Vassiliki, Davis, Suzanne E, Lippman, Scott M, Hong, Waun K

“…The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated,…”
Get more information